Trial Profile
A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The `F.I.R.E.' Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2012
Price :
$35
*
At a glance
- Drugs FX 06 (Primary)
- Indications Myocardial infarction; Myocardial reperfusion injury
- Focus Therapeutic Use
- Acronyms FIRE
- 06 Nov 2012 Planned number of patients changed from 140 to 220 as reported by European Clinical Trials Database record.
- 31 Mar 2009 Results of a prespecified subgroup analysis investigating effects of time to therapy were presented at the American College of Cardiology (ACC-2009).
- 24 Feb 2009 Results are published in Journal of the American College of Cardiology 53: 720-729, No. 8, 24 Feb 2009.